Presentation 1
Presentation 1
Presentation 1
Definition
Disease in which endometrial glands and stroma implant and grow in areas outside the lining of the uterine cavity most commonly on the ovaries, broad ligament, POD and uterosacral ligaments Can also be found on fallopian tube, bladder and large intestine and rarely in lungs, nasal passages and kidneys Endometriotic tissue responds to cyclical hormonal changes and therefore undergoes cyclical bleeding and local inflammatory reaction Healing and fibrosis can lead to adhesion between organs
Incidence
Present in 10-20% of women presenting to gynecologist Peak incidence between 30-45 years of age 25-50% of infertile women have endometriosis Remains as a hidden disease until other problems arise
Aetiology
Aetiology
Dissemination of endometrial cells through lymphatic and vascular systems. This explain the distant sites of endometriotic lesions Genetics - Studies have shown increased incidence in first-degree relatives of women with this disease Iatrogenic deposition of endometrial tissue has been found in some cases following gynecologic procedures and cesarean sections
Symptoms
Common - dysmenorrhea and pelvic pain Pelvic mass Alteration of menses Infertility Dyspareunia Bowel symptoms Urinary symptoms
Vaginal examination
Thickening or nodularity of uterosacral ligaments. Tenderness in the pouch of Douglas. Ovarian mass or mass due to adhesions of pelvic organs. Fixed retroverted uterus due to pelvic adhesions
Diagnosis
Ultrasound
- TVS can detect gross endometriosis involving the ovaries (endometrioma)
Staging
Stage I II Disease Minimal Mild Description A few superficial implants More and slightly deeper implants
III
Moderate
Many deep implants, small endometriomas on one or both ovaries, and some filmy adhesions Many deep implants, large endometriomas on one or both ovaries, and many dense adhesions, sometimes with the rectum adhering to the back of the uterus
IV
Severe
Infertility
Ovarian function Luteolysis caused by prostaglandins Oocyte maturation defects Anovulation Luteinized unruptured follicle syndrome Altered prolactin release Impaired fimbrial oocyte pick-up Altered tubal mobility Deep dyspareunia reduced coital frequency Antibodies causing inactivation Macrophage phagocytosis immune reaction Luteal phase deficiency
Tubal function
Management
Medical therapy - NSAIDs for pain relief - Combine oral contraceptive pills - Progestogens - Danazol - GnRH agonists
COCPs
Inhibiting ovulation Consist of synthetic estrogen and progesterone Prescribed to be taken continuously for an initial 6 mo To reduce the severity of dysmenorrhea and menstrual blood loss SE: weight gain, fluid retention, breast tenderness, arterial thrombosis, stroke, MI
progestogens
Synthetic drugs that mimic progesterone Medroxyprogesterone acetate has proven efficacy in pain suppression in both the oral and injectable depot preparations The use of levonogestrel intrauterine systems (LNGIUS) has been shown to be effective in achieving a long term therapy effect SE: weight gain, fluid retention, depression, and breakthrough bleeding
Danazol
synthetic version of the male hormone testosterone inhibits the release of FSH and LH by the pituitary gland decreases estrogen levels similar to menopause, stops ovulation improved symptoms in 89% of patients SE: deepening of the voice, abnormal hair growth, reduced breast size, water retention, weight gain , acne, irregular vaginal bleeding, muscle cramps Not commonly used agents due to alterations in lipid profile and liver function
GnRH agonists
GnRH analogs produce a hypogonadotrophichypogonadic state by down-regulation of the pituitary gland Treatment is usually restricted to monthly injections for 6 months. SE: reduced bone density, hot flashes and vaginal dryness Low estrogen effect: long term use can cause reduce bone density
Surgical treatment
Conservative surgery - laparoscopic with techniques such as diathermy, laser or excision - endometriotic cysts should not just be drained but the inner cyst lining should be excised and destroyed - LUNA is performed for uterosacral ligaments nodules - recurrent risk 30% and long term medical therapy is usually useful
Definitive surgery - severe symptoms or progressive disease or completed family - total abdominal hysterectomy with bilateral salpingo oopherectomy (TAH BSO)